TrialMarine drugs2009

Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium.

Herlinde Dumez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.